Evidence map›Paper›PMID 40108614›Full record

Observational studyBMC medical informatics and decision making2025

Evaluation and validation of a clinical decision support system for dose optimisation in hospitalized patients with (morbid) obesity - a retrospective, observational study.

Lianne Brand, L Mitrov-Winkelmolen, T M Kuijper, T M Bosch, L L Krens

Abstract readObservational StudyValidation Study
In one paragraph

Observational study in BMC medical informatics and decision making, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lianne BrandDepartment of Clinical Pharmacology and Toxicology, Maasstad Hospital, MaasstadLab, Rotterdam, The Netherlands. l.brand@lumc.nl.ORCID 0009-0009-9829-5647
L Mitrov-WinkelmolenHospital Pharmacy, Maasstad Hospital, Rotterdam, The Netherlands.ORCID 0000-0003-4133-2370
T M KuijperScience Bureau, Maasstad Hospital, Rotterdam, The Netherlands.ORCID 0000-0002-2834-5727
T M BoschDepartment of Clinical Pharmacology and Toxicology, Maasstad Hospital, MaasstadLab, Rotterdam, The Netherlands.ORCID 0000-0002-9337-7784
L L KrensHospital Pharmacy, Maasstad Hospital, Rotterdam, The Netherlands. KrensL@maasstadziekenhuis.nl.ORCID 0000-0003-3842-9585

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundObesity changes a patient's pharmacokinetics and pharmacotherapeutic advices should be personalized to ensure proper treatment. Currently, implementations of advices regarding the obese population are lacking and weight and body mass index (BMI) are rarely monitored. The Maasstad Hospital built a clinical decision support system (CDSS) for pharmacists, based on current Dutch guidelines, to supply therapeutic advices for (morbidly) obese patients based on patient characteristics. In this study we evaluated whether patients receiving inadequate pharmacotherapy are indeed identified via this CDSS and to which extent irrelevant alerts are generated. Moreover, it is investigated to which extent pharmacists carry on the generated advices and to which extent physicians act upon these.

methodsThe research concerned a retrospective observational study performed at the Maasstad Hospital in Rotterdam, the Netherlands between January 2021 and august 2021. The drugs included were dalteparin, apixaban, dabigatran, edoxaban, rivaroxaban, vancomycin and ciprofloxacin. Dispensing data, patient characteristics and CDSS processing were collected. Dispensing data was included when the patient's weight or BMI could potentially lead to dose adjustments via the CDSS. The CDSS was evaluated for sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Additionally, excess alerts, defined as irrelevant alerts on the moment of assessment, of the CDSS and adherence to the CDSS were investigated.

results1218 alerts over 3735 drug dispenses were generated. 568 alerts (46.6%) resulted in a pharmacotherapeutic advice by the pharmacist to the physician. In most cases, the sensitivity, specificity, PPV and NPV were 100.0% with varying 95% CIs. For some drugs technical adjustments were needed, including the initially incorrect BMI setting of vancomycin within the CDSS, resulting in a high excess alerts of 56.9%. Dabigatran had a NPV of 22.2% 95% CI [6.3-54.7] and a sensitivity of 56.3% 95% CI [33.2-76.9]. Overall excess alerts varied from 22.2% to 56.9%. Depending on the drug, the advices resulted in 6.9-100.0% real pharmacotherapy adjustments in practise.

conclusionThe (morbid) obesity CDSS functions as expected and identifies the (morbidly) obese patients with inadequate pharmacotherapy. The adherence of physicians and the follow-up in practise varies widely and requires further investigation.

trial registrationNon-WMO research W21.218.

Indexed as

Decision Support Systems, ClinicalObesity, MorbidAdultAgedFemaleHospitalizationHumansMaleMiddle AgedNetherlandsRetrospective StudiesAntibioticsAnticoagulantsClinical decision support systemEvaluationHospital pharmacy(Morbid) obesityPersonalized medicine

Identifiers

PMID40108614
PMCPMC11921672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.